Western Australian Premier Roger Cook says new national medical advice supports his state’s approach to transgender youth healthcare, as other Australian governments continue to impose or consider restrictions on puberty blockers.
The debate over gender-affirming healthcare for young people has intensified across Australia following the release of draft advice from the National Health and Medical Research Council (NHMRC).
Published for consultation on Monday 16 November 2026, the advice states that puberty suppressants can be considered as a treatment option for some transgender and gender-diverse young people under 18.
The recommendations emphasise comprehensive assessments, shared decision-making and ongoing medical monitoring.
Western Australian Premier Roger Cook welcomed the advice, arguing that it supports his government’s decision to retain access to the medication through appropriate healthcare services.
However, other Australian states are taking different approaches, highlighting an increasingly divided policy landscape.
‘Listen To The Experts,’ Says Roger Cook
Speaking to reporters, Cook said the NHMRC’s advice validated Western Australia’s approach to supporting transgender young people.
The Premier emphasised the importance of medical expertise when making decisions about deeply personal healthcare matters.
According to reporting by OUTinPerth on 19 November, Cook argued that politicians should listen to clinical experts rather than substitute political opinion for medical advice.
Western Australia is among the Australian states where eligible transgender and gender-diverse young people can access puberty suppressants following specialist assessment.
The NHMRC’s draft advice supports keeping the medication available as a possible treatment, rather than introducing a blanket approach for all patients.
For Cook, the recommendation aligns with the state’s existing clinical framework.
What Does The National Medical Advice Actually Say?
Puberty blockers, also known as puberty suppressants, are medications that temporarily suppress hormonal changes associated with puberty.
They have been used in paediatric healthcare for conditions including unusually early puberty and may also be considered for some transgender and gender-diverse young people.
The NHMRC recommends that clinicians consider puberty suppressants only after an individual assessment involving the young person and an appropriately qualified healthcare team.
Its proposed guidance includes:
- Comprehensive assessments of the young person’s health and circumstances.
- Shared decision-making involving the young person, parents or carers, and clinicians, as appropriate.
- Multidisciplinary support tailored to individual needs.
- Regular medical monitoring throughout treatment.
The council also recognises that not every transgender young person will want or benefit from puberty suppression.
Importantly, the draft advice does not require a young person to demonstrate distress about their gender incongruence in every case before treatment can be considered.
However, the NHMRC acknowledges that the available evidence has limitations, particularly regarding longer-term outcomes.
Its recommendation is therefore conditional and emphasises careful clinical oversight.
Queensland Is Taking A Different Approach
While Western Australia continues to permit treatment under its clinical arrangements, Queensland’s Government has maintained restrictions on new prescriptions of puberty blockers and gender-affirming hormones through public gender services.
The restrictions affect new patients under 18 seeking that care through Queensland’s public health system.
Following the NHMRC’s announcement, Queensland Deputy Premier Jarrod Bleijie rejected calls to reconsider the state’s position.
Families of transgender young people have continued advocating for access to care, arguing that the restrictions create uncertainty and barriers for those seeking specialist services.
Queensland’s policy does not constitute an Australia-wide ban.
Public gender services are administered by state and territory governments, meaning access can differ depending on where a young person lives.
The Northern Territory has also introduced restrictions affecting publicly provided treatment.
Victoria’s Opposition Wants Its Own Review
The issue has also entered Victoria’s state election campaign.
Opposition leader Jess Wilson has pledged that a Liberal and Nationals government would commission an independent review of puberty blocker prescribing through public hospitals and health services.
Wilson says Victoria should examine the evidence independently before making longer-term decisions.
However, the proposed review is an election commitment, not an immediate change to current prescribing rules.
Victoria’s Labor Government has indicated that it would follow national clinical guidance.
Victorians head to the polls on Saturday 28 November 2026.
Western Australian Liberals Disagree With Cook
Cook’s position is also being challenged by the Western Australian Liberal opposition.
Opposition health spokeswoman Libby Mettam has questioned the NHMRC’s approach and pointed to the United Kingdom’s Cass Review, which identified limitations in the available evidence concerning puberty blockers.
Mettam said the WA Liberal Party’s previous policy opposing puberty blockers and gender-affirming hormones for minors had not changed.
Her comments demonstrate that disagreements over access to gender-affirming healthcare continue within Western Australian politics, despite the Premier’s support for the national draft advice.
What Is Happening In Aotearoa?
Across the Tasman, New Zealand has experienced its own legal dispute over puberty blockers.
On 21 October 2026, the High Court set aside regulations restricting new prescriptions for young people experiencing gender dysphoria or gender incongruence.
The court identified deficiencies in the consultation process and found that the indefinite restriction breached the right to freedom from discrimination on the ground of disability.
Following the judgment, the Ministry of Health confirmed that clinicians could prescribe puberty blockers for young people with gender dysphoria or gender incongruence.
The Ministry has advised healthcare providers to take a holistic approach, including comprehensive assessment and consideration of medical, mental health and social support.
The court decision does not mean treatment is automatically appropriate for every patient.
Individual clinical decisions remain essential.
Australians Can Still Have Their Say
The NHMRC’s advice remains a draft open for public consultation.
Feedback will help inform Australia’s wider national clinical guidelines, which are expected in late 2028.
The national advice supports carefully assessed access for some trans young people, but the differing responses from state governments show that how those recommendations translate into healthcare remains an ongoing debate.

